The Latest Analyst Ratings for Travere Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Travere Therapeutics (NASDAQ:TVTX) within the last quarter, with a total of 3 bullish, 3 somewhat bullish, and 2 indifferent ratings. The average price target is $27.75, representing an upside from the current price of $13.725. However, this average represents a 4.31% decrease from the previous average price target of $29.00.
August 18, 2023 | 7:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics received mixed ratings from analysts, with an average price target of $27.75, indicating potential upside from the current price. However, the new average price target is a 4.31% decrease from the previous one.
The mixed ratings from analysts indicate uncertainty about the company's future performance. However, the average price target suggests potential upside, which could positively impact the stock price. The decrease in the average price target could be a concern, but it still represents a significant upside from the current price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100